Boston Globe Abbott Says Humira Gained activity Share in Crohn's, disease of the skin BusinessWeek July 20 (Bloomberg) -- Abbott Laboratories' top-selling Humira drug surged to a 25 percent second-quarter revenue gain by wresting sales from rival treatments for psoriasis and Crohn's disease, Chief Financial serviceman Thomas Freyman ... Abbott Labs 2Q profit grows with emerging markets The Associated Press Abbott posts 50% Q2 profit growth, revenues rise on pharmaceuticals Proactive Investors USA & Canada all 127 tidings articles » Link To Article
No comments:
Post a Comment